Looking to explore what supply strategies companies are using to support investigator-initiated studies.
In particular, for a situation using commercial supplies, are companies applying ancillary labels to the commercial pack – such as “clinical trial use only” statements or a protocol #?
If applying ancillary labels, what strategies/consideration is being given to the commercial label (avoid covering commercial label text?)